399 related articles for article (PubMed ID: 36706773)
1. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
Banwell B; Bennett JL; Marignier R; Kim HJ; Brilot F; Flanagan EP; Ramanathan S; Waters P; Tenembaum S; Graves JS; Chitnis T; Brandt AU; Hemingway C; Neuteboom R; Pandit L; Reindl M; Saiz A; Sato DK; Rostasy K; Paul F; Pittock SJ; Fujihara K; Palace J
Lancet Neurol; 2023 Mar; 22(3):268-282. PubMed ID: 36706773
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
[TBL] [Abstract][Full Text] [Related]
3. Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Martin K; Srikanth P; Kanwar A; Falardeau J; Pettersson D; Yadav V
Mult Scler Relat Disord; 2024 Jan; 81():105130. PubMed ID: 37979410
[TBL] [Abstract][Full Text] [Related]
4. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
Tajfirouz DA; Bhatti MT; Chen JJ
Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
[TBL] [Abstract][Full Text] [Related]
6. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
7. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome.
Wendel EM; Thonke HS; Bertolini A; Baumann M; Blaschek A; Merkenschlager A; Karenfort M; Kornek B; Lechner C; Pohl D; Pritsch M; Schanda K; Schimmel M; Thiels C; Waltz S; Wiegand G; Anlar B; Barisic N; Blank C; Breu M; Broser P; Della Marina A; Diepold K; Eckenweiler M; Eisenkölbl A; Freilinger M; Gruber-Sedlmayr U; Hackenberg A; Iff T; Knierim E; Koch J; Kutschke G; Leiz S; Lischetzki G; Nosadini M; Pschibul A; Reiter-Fink E; Rohrbach D; Salandin M; Sartori S; Schlump JU; Stoffels J; Strautmanis J; Tibussek D; Tüngler V; Utzig N; Reindl M; Rostásy K;
Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36229191
[TBL] [Abstract][Full Text] [Related]
8. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
Chen JJ; Bhatti MT
Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
[TBL] [Abstract][Full Text] [Related]
9. Relapsing MRI-negative myelitis associated with myelin-oligodendrocyte glycoprotein autoantibodies: a case report.
Kolcava J; Rajdova A; Vlckova E; Stourac P; Bednarik J
BMC Neurol; 2022 Aug; 22(1):313. PubMed ID: 36002821
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis, Clinical Features, and Treatment of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Autoantibody-Associated Disorders Focusing on Optic Neuritis with Consideration of Autoantibody-Binding Sites: A Review.
Tanaka K; Kezuka T; Ishikawa H; Tanaka M; Sakimura K; Abe M; Kawamura M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686172
[TBL] [Abstract][Full Text] [Related]
11. Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease.
Wang J; Yang K; Zhang F; Yi Y; Wang J
Mult Scler Relat Disord; 2023 Sep; 77():104879. PubMed ID: 37442076
[TBL] [Abstract][Full Text] [Related]
12. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases.
Guzmán J; Vera F; Soler B; Uribe-San-Martin R; García L; Del-Canto A; Schlatter A; Salazar M; Molt F; Ramirez K; Marín J; Pelayo C; Cruz JP; Bravo-Grau S; Cárcamo C; Ciampi E
Mult Scler Relat Disord; 2023 Jan; 69():104442. PubMed ID: 36521387
[TBL] [Abstract][Full Text] [Related]
13. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
Ciotti JR; Eby NS; Wu GF; Naismith RT; Chahin S; Cross AH
Mult Scler Relat Disord; 2020 Oct; 45():102399. PubMed ID: 32702642
[TBL] [Abstract][Full Text] [Related]
14. Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination.
Fadda G; Cardenas de la Parra A; O'Mahony J; Waters P; Yeh EA; Bar-Or A; Marrie RA; Narayanan S; Arnold DL; Collins DL; Banwell B;
Neurology; 2023 Jul; 101(4):e425-e437. PubMed ID: 37258297
[TBL] [Abstract][Full Text] [Related]
15. Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria.
Forcadela M; Rocchi C; San Martin D; Gibbons EL; Wells D; Woodhall MR; Waters PJ; Huda S; Hamid S
Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37977848
[TBL] [Abstract][Full Text] [Related]
16. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment.
Gospe SM; Chen JJ; Bhatti MT
Eye (Lond); 2021 Mar; 35(3):753-768. PubMed ID: 33323985
[TBL] [Abstract][Full Text] [Related]
17. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
18. Neuro-ophthalmological Presentation of Optic Neuritis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Lin TY; Asseyer S; Buenrostro GS; Feldmann K; Hamann S; Paul F; Zimmermann HG
Klin Monbl Augenheilkd; 2022 Nov; 239(11):1305-1314. PubMed ID: 35995144
[TBL] [Abstract][Full Text] [Related]
19. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
20. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis-A Review.
Kaushik M; Burdon MA
J Neuroophthalmol; 2021 Dec; 41(4):e786-e795. PubMed ID: 33870945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
